Limbird L E, Lefkowitz R J
J Biol Chem. 1976 Aug 25;251(16):5007-14.
(-)-[3H]Dihydroalprenolol, a potent competitive beta-adrenergic antagonist, has been previously documented to bind to the adenylate cyclase-coupled beta-adrenergic receptor sites in mammalian and non-mammalian tissues. Steady state binding of (-)-[3H]dihydroalprenolol to sites in frog erythrocyte membranes, a model system for adenylate cyclase-coupled beta-adrenergic receptors, displays characteristics consistent with negative cooperativity among the beta-adrenergic receptors: Scatchard plots are curvilinear with upward concavity and slopes of Hill plots are consistently less than 1.0. The existence of site-site interactions of the negatively cooperative type were demonstrated directly by the ability of unlabeled (-)-alprenolol to accelerate the dissociation of (-)-[3H]dihydroalprenolol under conditions were no rebinding of radioligand occurred. The dissociation rate of (-)-[3H]dihydroalprenolol alone is directly related to temperature and increases with increases in temperature from 4-37 degrees. (-)-[3H]Dihydroalprenolol dissociation is enhanced by unlabeled (-)-alprenolol at all temperatures studied; however, at 4 degrees, the time required to observe an enhancement of radioligand dissociated is greater than the time required for unlabeled (-)-alprenolol to occupy the empty receptor sites, suggesting that increased rigidity of the biomembrane at 4 degrees may be responsible for the absence of readily observable site-site interactions. The ability of a number of beta-adrenergic agonists and antagonists to induce negative cooperativity among the beta-adrenergic receptors was directly related to their affinity for the receptor sites rather than their intrinsic activity in the adenylate cyclase-coupled beta-adrenergic system. The ability to induce site-site interactions among the beta-adrenergic receptors occurs at physiological concentrations of beta-adrenergic agents, since occupancy of less than 10% of the receptor sites is sufficient to reduce receptor affinity. Changes in pH from 6.5 to 9.0 did not significantly alter the negatively cooperative site-site interactions among the receptor sites. The negatively cooperative phenomenon was also independent of Mg2+, Ca2+, and NaF concentrations in the buffer medium. The presence of guanyl-5'-yl imidodiphosphate, a nonhydrolyzable nucleotide analog which enhances adenylate cyclase stimulation (Vmax) by beta-adrenergic agonists and decreases the concentration of agonist required to half-maximally stimulate adenylate cyclase, did not alter the ability of either agonists or antagonists to induce negatively cooperative site-site interactions among the beta-adrenergic receptors.
(-)-[³H]二氢心得安是一种强效竞争性β-肾上腺素能拮抗剂,先前已有文献记载它能与哺乳动物和非哺乳动物组织中与腺苷酸环化酶偶联的β-肾上腺素能受体位点结合。(-)-[³H]二氢心得安与蛙红细胞膜上的位点(腺苷酸环化酶偶联β-肾上腺素能受体的模型系统)的稳态结合显示出与β-肾上腺素能受体之间负协同性一致的特征:Scatchard图呈向上凹的曲线,Hill图的斜率始终小于1.0。未标记的(-)-心得安在无放射性配体再结合的条件下加速(-)-[³H]二氢心得安解离的能力直接证明了负协同类型的位点间相互作用的存在。单独的(-)-[³H]二氢心得安的解离速率与温度直接相关,并且随着温度从4℃升高到37℃而增加。在所有研究的温度下,未标记的(-)-心得安都会增强(-)-[³H]二氢心得安的解离;然而,在4℃时,观察到放射性配体解离增强所需的时间大于未标记的(-)-心得安占据空受体位点所需的时间,这表明4℃时生物膜刚性增加可能是缺乏易于观察到的位点间相互作用的原因。许多β-肾上腺素能激动剂和拮抗剂诱导β-肾上腺素能受体之间负协同性的能力与其对受体位点的亲和力直接相关,而不是与其在腺苷酸环化酶偶联β-肾上腺素能系统中的内在活性相关。β-肾上腺素能药物在生理浓度下就能诱导β-肾上腺素能受体之间的位点间相互作用,因为占据不到10%的受体位点就足以降低受体亲和力。pH从6.5变为9.0并没有显著改变受体位点之间的负协同位点间相互作用。负协同现象也与缓冲介质中的Mg²⁺、Ca²⁺和NaF浓度无关。鸟苷-5'-基亚氨基二磷酸(一种不可水解的核苷酸类似物,可增强β-肾上腺素能激动剂对腺苷酸环化酶的刺激作用(Vmax)并降低半最大刺激腺苷酸环化酶所需的激动剂浓度)的存在并没有改变激动剂或拮抗剂诱导β-肾上腺素能受体之间负协同位点间相互作用的能力。